Alnylam Pharmaceuticals Balance Sheet
NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alnylam Pharmaceuticals financial position
At the end of fiscal 2025, Alnylam Pharmaceuticals reported total assets of $4.97 billion, up 17.1% from a year earlier against total liabilities of $4.18 billion. Shareholders' equity stood at $789.2 million, or 15.9% of assets. The company held $1.66 billion in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.76, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Alnylam Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.66B | 966.43M | 812.69M | 866.39M | 819.98M | 496.58M | 547.18M | 420.15M | 645.36M | 193.62M |
| Short-Term Investments | 1.25B | 1.72B | 1.62B | 1.30B | 1.55B | 1.33B | 975.02M | 662.80M | 1.05B | 424.19M |
| Receivables | 777.57M | 405.31M | 327.79M | 237.96M | 198.57M | 102.41M | 43.01M | 18.76M | 34.00M | 23.33M |
| Inventory | 82.72M | 78.51M | 89.15M | 128.96M | 86.36M | 75.20M | 56.35M | 24.07M | — | — |
| Total Current Assets | 4.05B | 3.30B | 2.98B | 2.69B | 2.81B | 2.61B | 1.72B | 1.20B | 1.76B | 671.88M |
| Property, Plant & Equipment | 513.15M | 502.78M | 526.06M | 523.49M | 501.96M | 465.03M | 425.18M | 320.66M | 181.90M | 114.57M |
| Long-Term Investments | — | — | — | — | — | — | — | — | 13.92M | 324.80M |
| Total Assets | 4.97B | 4.24B | 3.83B | 3.55B | 3.64B | 3.41B | 2.40B | 1.57B | 1.99B | 1.26B |
| Accounts Payable | 115.72M | 88.42M | 55.52M | 98.09M | 73.43M | 51.97M | 49.88M | 59.71M | 28.36M | 54.47M |
| Total Current Liabilities | 1.47B | 1.19B | 967.79M | 767.91M | 695.71M | 585.27M | 352.59M | 179.49M | 144.25M | 131.70M |
| Long-Term Debt | — | — | — | — | 675.70M | 191.28M | — | — | — | — |
| Total Liabilities | 4.18B | 4.17B | 4.05B | 3.70B | 3.06B | 2.39B | 956.44M | 272.84M | 228.30M | 342.59M |
| Shareholders' Equity | 789.18M | 67.09M | -220.64M | -158.22M | 588.20M | 1.02B | 1.44B | 1.30B | 1.77B | 920.22M |
| Retained Earnings | -6.70B | -7.29B | -7.01B | -6.57B | -5.44B | -4.59B | -3.73B | -2.84B | -2.15B | -1.66B |
| Total Debt | — | — | — | — | 675.70M | 191.28M | — | — | — | — |
| Net Cash (Debt) | 2.91B | 2.69B | 2.43B | 2.16B | 1.69B | 1.64B | 1.52B | 1.08B | 1.69B | 617.80M |
| Shares Outstanding | 132.38M | 129.29M | 125.79M | 123.92M | 120.18M | 116.43M | 112.19M | 101.18M | 99.67M | 85.94M |
This table shows 10 annual periods of Alnylam Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ALNY's reporting calendar. What is a balance sheet?